Preclinical
September 4, 2024
World Bispecific Summit
Leveraging Azymetric to Optimally Format T-Cell Engagers and Bispecific ADCs
Paul Moore
Preclinical
August 21, 2024
ACS
Design and selection of the novel camptothecin analog ZD06519: A payload optimized for antibody-drug conjugates
Brant et al.
Preclinical
August 7, 2024
Immuno-Oncology Summit
Building Differentiated & Next Generation T Cell Engagers to Improve Responses in Difficult-to-Treat Tumors.
Nicole Afacan
Preclinical
June 23, 2024
ADCS National Medicinal Chemistry Symposium
Development of a Novel TOPO1i ADC Platform: From Concept to Pipeline Application
Mark Petersen
Preclinical
May 16, 2024
PEGS
Screening Novel Format Antibodies to Design Bispecific ADCs that Address Target Heterogeneity
Dunja Urosev
Preclinical
May 16, 2024
PEGS
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and antitumor responses in hard-to-treat cancers
Newhook et al.
Preclinical
April 17, 2024
Festival of Biologics
Next Generation Trispecific T Cell Engagers (TriTCE) Designed to Improve Treatment Responses in Oncology
Genevieve Desjardins
Preclinical
April 10, 2024
AACR
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
Newhook et al.
Preclinical
April 10, 2024
AACR
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
Repenning et al.
Preclinical
April 8, 2024
AACR
Development of three-dimensional cancer cell line spheroid models for the in vitro functional
characterization of cytotoxic antibody-drug conjugates
Wong et al.
Preclinical
April 8, 2024
AACR
Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
Barnscher et al.
Preclinical
April 8, 2024
AACR
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
Lawn et al.
